Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea

Hydroxyurea is the gold standard treatment for prevention of vaso-occlusive crises in patients with sickle-cell anaemia. It has a narrow therapeutic index and dangerous side effects including cytopenias. There is high variation in dose–response across the population. Therefore, a robust outpatient m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, Joel, Lewis, Natasha, Tsitsikas, Dimitris A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
BMJ Quality Improvement Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878251/
https://www.ncbi.nlm.nih.gov/pubmed/29610772
http://dx.doi.org/10.1136/bmjoq-2017-000218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878251/
https://www.ncbi.nlm.nih.gov/pubmed/29610772
http://dx.doi.org/10.1136/bmjoq-2017-000218

Ejemplares similares